)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Novakand Pharma
Novakand Pharma (NOVKAN) investor relations material
Novakand Pharma has been delisted
Novakand Pharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Strategic shift from cardiovascular to orphan drug development for advanced ovarian cancer and leukemia, targeting patient groups lacking adequate treatments.
Nasdaq delisted the company in April 2026 after failed acquisition and lack of qualifying operations; new board and management appointed.
Focus on leveraging clinical results from the Kandova study and preparing for a pivotal clinical trial in 2028.
Financial highlights
Net sales remained at SEK 0.0 million (0.0) for H1 2026.
R&D expenses decreased sharply to SEK 2.5 million (15.8) year-over-year.
Operating loss improved to SEK -6.3 million (-19.5) compared to H1 2025.
Net loss after financial items was SEK -6.3 million (-19.2).
Cash flow from operations was SEK -7.1 million (-18.8); cash at period end SEK 9.0 million (27.6).
Outlook and guidance
Preparing for a rights issue in Q4 2026 to fund readiness for a pivotal clinical study starting in 2028.
Additional capital raise planned for 2027 to finance the clinical study through 2030.
Company expects current cash to cover basic operations until at least Q1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Novakand Pharma
- Cash reached SEK 106.5m as KAND567 and KAND145 advanced toward clinical milestones.NOVKAN
Q4 2021 - FRACTAL signals advanced pivotal-study plans as cash pressures drove a planned rights issue.NOVKANQ4 2023
- Clinical pipeline advanced despite a SEK 52.5m loss and continued dependence on financing.NOVKANQ4 2022
- Reverse acquisition of SVF Vaccines is pivotal amid reduced losses and risk of delisting.NOVKANQ4 2025
- Reverse takeover pursued after failed financing; SEK 18M asset write-down and cost cuts enacted.NOVKANQ3 2025
- Clinical milestones achieved, losses narrowed, but future activities hinge on new funding.NOVKANQ2 2025
- Strategic pivot to cardiovascular R&D, with strong cash position and high commercial potential.NOVKANQ3 2024
- Clinical milestones and improved financials position Kancera for continued development and partnerships.NOVKANQ2 2024
- Strategic pivot to cardiovascular R&D and cost discipline position Kancera for next clinical phase.NOVKANQ4 2024
Next Novakand Pharma earnings date
H2 202619 Feb, 2027
Novakand Pharma
Next Novakand Pharma earnings date
H2 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kancera AB is a Swedish biotechnology company focusing on developing pharmaceuticals for the treatment of severe diseases, particularly cancer and inflammatory conditions. The company's efforts are primarily directed towards creating small molecule drug candidates that target disease-promoting immune and cancer cells, specifically utilizing the fractalkine axis. Kancera's work is divided into two main areas: Pharmaceutical Development and Industrial Research and Development (R&D). Solna, Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.